Cargando…

Machine Learning algorithm unveils glutamatergic alterations in the post-mortem schizophrenia brain

Schizophrenia is a disorder of synaptic plasticity and aberrant connectivity in which a major dysfunction in glutamate synapse has been suggested. However, a multi-level approach tackling diverse clusters of interacting molecules of the glutamate signaling in schizophrenia is still lacking. We inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Rosa, Arianna, Fontana, Andrea, Nuzzo, Tommaso, Garofalo, Martina, Di Maio, Anna, Punzo, Daniela, Copetti, Massimiliano, Bertolino, Alessandro, Errico, Francesco, Rampino, Antonio, de Bartolomeis, Andrea, Usiello, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881508/ https://www.ncbi.nlm.nih.gov/pubmed/35217646 http://dx.doi.org/10.1038/s41537-022-00231-1

Ejemplares similares

Abnormal RasGRP1 Expression in the Post-Mortem Brain and Blood Serum of Schizophrenia Patients
por: De Rosa, Arianna, et al.
Publicado: (2022)

Analysis of mRNA and Protein Levels of CAP2, DLG1 and ADAM10 Genes in Post-Mortem Brain of Schizophrenia, Parkinson’s and Alzheimer’s Disease Patients
por: Di Maio, Anna, et al.
Publicado: (2022)

Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients
por: Nuzzo, Tommaso, et al.
Publicado: (2017)

The Emerging Role of Altered d-Aspartate Metabolism in Schizophrenia: New Insights From Preclinical Models and Human Studies
por: Errico, Francesco, et al.
Publicado: (2018)

DNA methylation landscape of the genes regulating D-serine and D-aspartate metabolism in post-mortem brain from controls and subjects with schizophrenia
por: Keller, Simona, et al.
Publicado: (2018)

The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment
por: Iasevoli, Felice, et al.
Publicado: (2014)

A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice
por: Errico, F, et al.
Publicado: (2015)

New Evidence on the Role of D-Aspartate Metabolism in Regulating Brain and Endocrine System Physiology: From Preclinical Observations to Clinical Applications
por: Usiello, Alessandro, et al.
Publicado: (2020)

Glutamatergic dysfunction in Schizophrenia
por: Kruse, Andreas O., et al.
Publicado: (2022)

Selective demethylation of two CpG sites causes postnatal activation of the Dao gene and consequent removal of d-serine within the mouse cerebellum
por: Cuomo, Mariella, et al.
Publicado: (2019)

The striatal-enriched protein Rhes is a critical modulator of cocaine-induced molecular and behavioral responses
por: Napolitano, Francesco, et al.
Publicado: (2019)

Towards a framework for treatment effectiveness in schizophrenia
por: Juckel, Georg, et al.
Publicado: (2014)

Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity
por: Sacchi, Silvia, et al.
Publicado: (2017)

Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice
por: Guida, F., et al.
Publicado: (2015)

D-aspartate oxidase gene duplication induces social recognition memory deficit in mice and intellectual disabilities in humans
por: Lombardo, Barbara, et al.
Publicado: (2022)

T10. HERITABILITY OF AMYGDALA ACTIVITY AND ITS GENOME WIDE ASSOCIATION WITH THE SCHIZOPHRENIA RISK LOCUS OF MIR137
por: Quarto, Tiziana, et al.
Publicado: (2018)

Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia
por: Goldstein, Meghan Elizabeth, et al.
Publicado: (2015)

Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies
por: Panariello, Fabio, et al.
Publicado: (2011)

T197. A DRD2 CO-EXPRESSION GENE SET ENRICHED FOR SCHIZOPHRENIA RISK GENES IS CHARACTERIZED BY A COMMON TRANSCRIPTIONAL REGULATION INVOLVING NURR1 TRANSCRIPTION FACTOR
por: Torretta, Silvia, et al.
Publicado: (2018)

Similarities and differences between multivariate patterns of cognitive and socio-cognitive deficits in schizophrenia, bipolar disorder and related risk
por: Raio, Alessandra, et al.
Publicado: (2023)

The Role of Autopsy and Post-Mortem Investigations in Falling Traumas in the Hospital Environment
por: Sacco, Matteo Antonio, et al.
Publicado: (2022)

The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients
por: Nuzzo, Tommaso, et al.
Publicado: (2019)

The Integration of the Glutamatergic and the White Matter Hypotheses of Schizophrenia’s Etiology
por: Dias, Alvaro Machado
Publicado: (2012)

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
por: Fedorenko, Olga Yu., et al.
Publicado: (2022)

Corrigendum to: Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia
Publicado: (2023)

The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2023)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis, Andrea, et al.
Publicado: (2016)

Crystal Structure of the DFNKF Segment of Human Calcitonin Unveils Aromatic Interactions between Phenylalanines
por: Bertolani, Arianna, et al.
Publicado: (2016)

Immune environment of the brain in schizophrenia and during the psychotic episode: A human post-mortem study
por: De Picker, Livia J., et al.
Publicado: (2021)

Disrupted-in-Schizophrenia (DISC1) Functions Presynaptically at Glutamatergic Synapses
por: Maher, Brady J., et al.
Publicado: (2012)

O9.4. PREDICTING SCHIZOPHRENIA: IDENTIFICATION OF MULTIMODAL MARKERS OF DISEASE THROUGH A MACHINE LEARNING APPROACH
por: Antonucci, Linda, et al.
Publicado: (2018)

Heritability of amygdala reactivity to angry faces and its replicable association with the schizophrenia risk locus of miR-137
por: Quarto, Tiziana, et al.
Publicado: (2023)

Involvement of Gut Microbiota in Schizophrenia and Treatment Resistance to Antipsychotics
por: Manchia, Mirko, et al.
Publicado: (2021)

Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
por: de Bartolomeis, Andrea, et al.
Publicado: (2022)

Glutamatergic Dysfunction and Synaptic Ultrastructural Alterations in Schizophrenia and Autism Spectrum Disorder: Evidence from Human and Rodent Studies
por: Eltokhi, Ahmed, et al.
Publicado: (2020)

Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia
por: Bitanihirwe, BKY, et al.
Publicado: (2009)

S14. DNA METHYLATION CHANGES IN GABAERGIC AND GLUTAMATERGIC MARKERS IN EARLY SCHIZOPHRENIA
por: Fachim, Helene, et al.
Publicado: (2018)

Glutamatergic Deficits in Schizophrenia – Biomarkers and Pharmacological Interventions within the Ketamine Model
por: Haaf, Moritz, et al.
Publicado: (2018)

Risk-Conferring Glutamatergic Genes and Brain Glutamate Plus Glutamine in Schizophrenia
por: Bustillo, Juan R., et al.
Publicado: (2017)

mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia
por: Wang, Hoau-Yan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u7t89v222gpp8gcf7a8f507rou